| Title |
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, April 2017
|
| DOI | 10.2147/dmso.s130834 |
| Pubmed ID | |
| Authors |
Philip A Levin, Hiep Nguyen, Eric T Wittbrodt, Seoyoung C Kim |
| Abstract |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety. Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed. A literature search was performed using MEDLINE and Embase databases to identify papers comparing GLP-1RAs with other classes of glucose-lowering therapy in patients with T2D. Of the 1303 papers identified, 57 met the prespecified criteria for a high-quality clinical trial or retrospective study. The efficacy and tolerability of approved GLP-1RAs (exenatide twice daily or once weekly, dulaglutide, liraglutide, lixisenatide, and albiglutide) were compared with insulin products (23 prospective studies + seven retrospective studies), dipeptidyl peptidase-4 inhibitors (11 prospective studies + three retrospective studies), sulfonylureas (nine prospective studies + one retrospective study), thiazolidinediones (five prospective studies), and metformin (two prospective studies). GLP-1RAs are effective as a second-line therapy in improving glycemic parameters in patients with T2D. Reductions in glycated hemoglobin from baseline with GLP-1RAs tended to be greater or similar compared with insulin therapy. GLP-1RAs were consistently more effective in reducing body weight than most oral glucose-lowering drugs and insulin and were associated with lower hypoglycemia risk versus insulin or sulfonylureas. GLP-1RAs improved cardiovascular risk factors, and preliminary data suggest they improve cardiovascular outcomes in patients with T2D compared with oral glucose-lowering drugs. However, results from ongoing studies are awaited to confirm these early findings. This systematic review found that GLP-1RAs are an effective class of glucose-lowering drugs for T2D. |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 113 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 20% |
| Student > Master | 15 | 13% |
| Student > Ph. D. Student | 10 | 9% |
| Student > Postgraduate | 8 | 7% |
| Student > Bachelor | 7 | 6% |
| Other | 16 | 14% |
| Unknown | 34 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Nursing and Health Professions | 4 | 4% |
| Economics, Econometrics and Finance | 4 | 4% |
| Other | 8 | 7% |
| Unknown | 39 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2019.
All research outputs
#8,621,995
of 25,593,129 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#353
of 1,193 outputs
Outputs of similar age
#127,953
of 324,467 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#4
of 11 outputs
Altmetric has tracked 25,593,129 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,193 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,467 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.